Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
To assess the efficacy of adjunctive hemoperfusion (HP) in improving toxin clearance, systemic inflammation and clinical outcomes in children with chronic kidney disease (CKD) undergoing maintenance hemodialysis (M-HD).
Five children (median age 13.2 years, range 10–16) on adequate M-HD, but with resistant hypertension, persistent pruritus, sleep disturbances or reduced appetite, were prospectively enrolled from June 2025. HP was integrated into HD session once weekly for 1 month then tapered to biweekly in second month. The HP treatment was conducted using Jafron HA 130 filter. Clinical outcomes- blood pressure, antihypertensive requirement, pruritus scores (Visual Analog Scale), sleep quality (Epworth Sleepiness Scale- EPSS) and quality of life (KDQOL- SF 1.3). Laboratory outcomes- serum β2-microglobulin (β2-MG) and interleukin-6 (IL-6) measured at baseline and over time. Data are expressed as mean ± SD, with trends analysed using repeated-measures ANOVA.
Mean baseline serum β2-MG (38.14 ± 5.1 mg/L) showed significant reduction to 31.8 ± 4.3 at 2 weeks, 30.1 ± 3.9 at 4 weeks and 31.3 ± 4.0 at 6 weeks (p=0.02). IL-6 declined from 34.2 ± 6.2 pg/mL at baseline to 12.1 ± 3.1, 11.3 ± 2.7, and 8.9 ± 2.5 at 2, 4 and 6 weeks respectively (p<0.001). The mean number of antihypertensives decreased from 4.0 ± 0.7 to 2.2 ± 0.4 (p=0.01). EPSS scores dropped from 14.8 ± 2.1 to 8.6 ± 1.7 (p=0.008) while pruritus scores improved from 8.0 ± 1.3 to 4.8 ± 0.9 (p=0.01). KDQOL- SF 1.3 domains of physical functioning, vitality and emotional well-being each improved by >20% compared to baseline.
There is a paucity of published data on the use of HP in pediatric CKD patients on M-HD. In this study, adjunctive HP with M-HD showed statistically significant reductions in serum β2-MG, IL-6, improved blood pressure control, enhanced sleep, pruritus outcomes and improvements in quality of life supporting HP as a promising adjunct therapy by providing biochemical and symptomatic relief in addition to better long-term cardiovascular and neurocognitive outcomes in CKD patients.
